{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:34:20Z","timestamp":1787168060203,"version":"build-2736575974"},"reference-count":32,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      The gp120\u2010directed attachment inhibitor fostemsavir was effective in people with multidrug\u2010resistant (MDR) HIV\u20101 in the BRIGHTE study. Understanding factors associated with virologic response can help clinicians optimize treatment and identify individuals for fostemsavir\u2010based regimens. In previous multivariable analyses, baseline CD4+ T\u2010cell count, baseline log\n                      <jats:sub>10<\/jats:sub>\n                      HIV\u20101 RNA and temsavir plasma concentration were associated with virologic response through 24\u2009weeks. This expanded analysis evaluated predictors of the durability of response at Weeks 96 and 192.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      BRIGHTE participant data (Randomized Cohort [RC],\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009272; Non\u2010randomized Cohort,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200999) were evaluated to examine baseline factors associated with virologic outcomes (HIV\u20101 RNA &lt;40 copies\/mL [Snapshot]; protocol\u2010defined virologic failure [PDVF]) using linear\/logistic regression with stepwise selection. A separate analysis evaluated baseline factors for association with treatment\u2010adherent PDVF.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In RC participants, higher baseline log\n                      <jats:sub>10<\/jats:sub>\n                      HIV\u20101 RNA, lower number of fully active available antiretrovirals in initial optimized background therapy (OBT) and a lower overall susceptibility score to newly used antiretrovirals in initial OBT were associated with lower odds of virologic response at Week 96. Baseline gp120 substitutions and dolutegravir use were additional factors through Week 192. Other baseline factors, including CD4+ T\u2010cell count &lt;20 cells\/mm\n                      <jats:sup>3<\/jats:sup>\n                      , HIV\u20101 RNA \u2265100\u2009000 copies\/mL, antiretroviral therapy duration &gt;20\u2009years or gp120 substitutions, had low predictive value for treatment\u2010adherent PDVF in RC participants (Week 96, 35%; Week 192, 39%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Multivariable analysis (MVA) identified several factors predictive of virologic response. No baseline factors were highly predictive of virologic failure at Weeks 96 or 192. Findings support the use of fostemsavir in diverse populations with MDR HIV\u20101.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hiv.70154","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T02:22:21Z","timestamp":1765592541000},"page":"386-396","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploring the impact of baseline and on\u2010treatment variables on durability of responses to fostemsavir through weeks 96 and 192 in the phase 3\n                    <scp>BRIGHTE<\/scp>\n                    study"],"prefix":"10.1111","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1200-3706","authenticated-orcid":false,"given":"M.","family":"Gartland","sequence":"first","affiliation":[{"name":"ViiV Healthcare  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Wang","sequence":"additional","affiliation":[{"name":"ViiV Healthcare  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Liao","sequence":"additional","affiliation":[{"name":"ViiV Healthcare  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Li","sequence":"additional","affiliation":[{"name":"GSK  Collegeville Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Du","sequence":"additional","affiliation":[{"name":"GSK  Collegeville Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Krystal","sequence":"additional","affiliation":[{"name":"ViiV Healthcare  Branford Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. R.","family":"Tenorio","sequence":"additional","affiliation":[{"name":"ViiV Healthcare  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pierce","sequence":"additional","affiliation":[{"name":"ViiV Healthcare  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. R.","family":"Castillo\u2010Mancilla","sequence":"additional","affiliation":[{"name":"ViiV Healthcare  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"Juluca [prescribing information]. Durham NC: ViiV Healthcare.2025."},{"key":"e_1_2_10_3_1","unstructured":"Dovato [prescribing information]. Durham NC: ViiV Healthcare.2025."},{"key":"e_1_2_10_4_1","unstructured":"Cabenuva [product monograph]. Montreal Canada: ViiV Healthcare ULC.2025."},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-041217-013717"},{"key":"e_1_2_10_6_1","unstructured":"Rukobia [prescribing information]. Durham NC: ViiV Healthcare.2024."},{"key":"e_1_2_10_7_1","unstructured":"Trogarzo [prescribing information]. Montreal Canada: Theratechnologies Inc.2023."},{"key":"e_1_2_10_8_1","unstructured":"Cabenuva [prescribing information]. Durham NC: ViiV Healthcare.2025."},{"key":"e_1_2_10_9_1","unstructured":"Sunlenca [prescribing information]. Foster City CA: Gilead Sciences Inc.2024."},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/2049936120901395"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/11587420-000000000-00000"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13288"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab562"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835584ea"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001967"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002635"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/prot.24726"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00426-12"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04914-14"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02251-21"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00513-13"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2024.105957"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902493"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-023-00870-6"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002851"},{"key":"e_1_2_10_26_1","volume-title":"Presented at: HIV Drug Therapy Glasgow","author":"Gartland M","year":"2022"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt412"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31829726f3"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01173-10"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01751-21"},{"key":"e_1_2_10_31_1","volume-title":"Presented at: Conference on Retroviruses and Opportunistic Infections; 2023, Seattle","author":"Ogbuagu O","year":"2023"},{"key":"e_1_2_10_32_1","article-title":"Fostemsavir resistance in clinical context: a narrative review","volume":"12","author":"Schapiro JM","year":"2025","journal-title":"Ther Adv Infect Dis"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad370"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70154","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hiv.70154","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70154","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T10:55:49Z","timestamp":1773399349000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.70154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1111\/hiv.70154"],"URL":"https:\/\/doi.org\/10.1111\/hiv.70154","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"2025-06-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}